Orphan designation: post-authorisation
The pages listed below are relevant for sponsors of medicines that have obtained orphan designation and are at the post-authorisation stage of the product lifecycle.
Rare diseases
Sponsors of designated orphan medicines at the post-authorisation stage should also consider the regulatory information in the sections below: